Pipelines
Addressing Unmet Needs in Companion Animal Medicine
Each program in the LE-AD series targets a condition
where current treatments are insufficient
— and where the immunomodulatory mechanism of species-specific exosomes offers
a scientifically grounded therapeutic rationale.
LE-AD-101 (canine MSC-derived exosome)
canine Atopic Dermatitis / preclinical
Chronic, relapsing inflammatory skin disease affecting an estimated 10–15% of dogs worldwide.
Existing treatments manage symptoms but do not address underlying immune dysregulation.
LE-AD-201 (feline MSC-derived exosome)
feline Gingivostomatitis(FCGS) / preclinical
A severe, immune-mediated oral inflammatory condition in cats.
No approved pharmacological treatment exists. Surgical extraction remains the standard of care.
feline chronic kidney disease(FCKD) / preclinical
The leading cause of mortality in cats. No approved disease-modifying treatment exists.
Our approach targets immune-mediated fibrotic progression through systemic immunomodulation.
